Abeona Therapeutics Inc. (ABEO) – What Are Brokerages Thinking About This Stock?

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) have earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $21.00.

ABEO has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Abeona Therapeutics in a research note on Friday, September 25th. Cantor Fitzgerald raised their price objective on Abeona Therapeutics from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, September 18th. UBS Group restated a “buy” rating on shares of Abeona Therapeutics in a research note on Friday, September 25th. Oppenheimer restated an “outperform” rating and set a $21.00 price objective (down from $22.00) on shares of Abeona Therapeutics in a report on Friday, August 14th. Finally, Weiss Ratings lowered Abeona Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, August 17th.

Abeona Therapeutics Stock Performance

Shares of ABEO stock opened at $4.90 on Tuesday. Abeona Therapeutics has a 12 month low of $4.00 and a 12 month high of $7.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.63 and a quick ratio of 6.40. The firm has a market capitalization of $280.18 million, a P/E ratio of -4.50 and a beta of 1.31. The company’s fifty day moving average price is $5.84 and its two-hundred day moving average price is $5.75.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.12). The business had revenue of $11.38 million for the quarter, compared to the consensus estimate of $12.24 million. On average, research analysts anticipate that Abeona Therapeutics will post -0.88 earnings per share for the current fiscal year.

Insider Buying and Selling at Abeona Therapeutics

In related news, CEO Vishwas Seshadri sold 19,608 shares of Abeona Therapeutics stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $5.16, for a total value of $101,177.28. Following the completion of the sale, the chief executive officer owned 1,286,500 shares in the company, valued at approximately $6,638,340. The trade was a 1.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Madhav Vasanthavada sold 4,902 shares of the company’s stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $5.16, for a total transaction of $25,294.32. Following the completion of the sale, the insider directly owned 285,721 shares in the company, valued at $1,474,320.36. This represents a 1.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 56,906 shares of company stock valued at $306,160. Corporate insiders own 7.10% of the company’s stock.

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. WINTON GROUP Ltd acquired a new stake in shares of Abeona Therapeutics in the 2nd quarter valued at about $256,000. Corient Private Wealth LP bought a new position in shares of Abeona Therapeutics during the second quarter worth about $556,000. Pale Fire Capital SE grew its stake in Abeona Therapeutics by 17.3% in the second quarter. Pale Fire Capital SE now owns 81,945 shares of the biopharmaceutical company’s stock worth $506,000 after purchasing an additional 12,100 shares in the last quarter. Headlands Technologies LLC grew its stake in Abeona Therapeutics by 97.5% in the second quarter. Headlands Technologies LLC now owns 125,090 shares of the biopharmaceutical company’s stock worth $773,000 after purchasing an additional 61,745 shares in the last quarter. Finally, AWM Investment Company Inc. acquired a new position in Abeona Therapeutics in the second quarter worth about $9,184,000. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a biotechnology company focused on developing and commercializing cell and gene therapies for serious diseases. The company’s primary focus is regenerative medicine, with an emphasis on treatments that address rare genetic disorders and conditions involving damaged or absent tissue.

Abeona’s lead product, ZEVASKYN (prademagene zamikeracel, formerly EB-101), is an autologous, gene-corrected cell therapy for wounds associated with recessive dystrophic epidermolysis bullosa (RDEB).